Follistatin-344 is a large (~38 kDa) glycoprotein, NOT a small peptide, that inhibits both myostatin and activin A, the TGF-β-family signals that normally suppress muscle growth.
Follistatin-344 Prices
4 vendors · 1 with an issuer-verified COA · lowest 10mg from $849.92 · checked
Where to buy Follistatin-344: 4 vendors compared
| Vendor | Price | Actions |
|---|---|---|
| 3-test panelVerified COAJanoshik · Tested May 28, 2026 | $849.92 | Buy Follistatin-344 from SomaChems |
| $1104.0010 × 1mg packages · 10mg totalChecked Sep 30 | Buy Follistatin-344 from StrikePoint Peptides | |
| $1190.0010 × 1mg packages · 10mg totalChecked today | Buy Follistatin-344 from True Research Labs | |
| $1736.13 | Buy Follistatin-344 from Paramount Peptides |
Tracked every day
Follistatin-344 listing prices, tracked daily
The five cheapest in-stock package prices for Follistatin-344 on each collected day, and the vendors that most often held those places.
Five cheapest in-stock package prices per day
Listed package price before coupons, any vial size. This is not the coupon-adjusted lowest 10mg price used to rank the comparison.
- Cheapest$119.00
- 2nd cheapest$182.75
Vendors most often in the cheapest five
- True Research Labs21 days$119.000.0%
- Paramount Peptides8 days$182.750.0%
- StrikePoint Peptides1 day$110.40last seen Sep 30, 20260.0%
Current market data
Follistatin-344 Price Report
A current summary of public listings after the price comparison above. Shipping and tax are not included.
The lowest current 10mg cost for Follistatin-344 is $849.92 from SomaChems. The median across vendors is $1147.00.
- Lowest 10mg cost
- $849.92SomaChems
- Median 10mg cost
- $1147.00One normalized offer per vendor
- Lowest package total
- $84.99SomaChems · package size may differ
- Public COA coverage
- 100%4 of 4 vendors
What the market shows
PeptidePrices found 4 in-stock listings from 4 vendors, checked through Oct 9, 2026. The lowest 10mg cost is 26% below the vendor median of $1147.00; 2 vendors (50%) fall below that median. 4 of 4 vendors (100%) publish public COA evidence.
A public COA link shows that a vendor publishes testing data. It does not prove that every listed vial has a matching current report. Match the product, strength, batch, and lot before relying on a report.
How this report is calculated
The headline and median use each vendor's lowest whole-package checkout cost to obtain at least 10mg. Smaller packages are multiplied until the target is met, while larger packages retain their full checkout price. The lowest package total is shown only as secondary context because package sizes differ. Known public coupon discounts are applied. Shipping, tax, and unverified promotions are excluded.
Research context
What is Follistatin-344? Research, safety, and status
Follistatin-344 (FS-344) is a naturally occurring glycoprotein studied for muscle growth and as a therapy for muscular dystrophy. It works by neutralizing the body's brakes on muscle, myostatin and activin A, and in gene-therapy form has produced large, durable muscle gains in animals and meaningful function gains in human muscular-dystrophy trials.
Key research takeaways
Follistatin-344 at a glance
PeptidePrices safety rating
4/10 · Not FDA-approved
Mechanism
Endogenous glycoprotein; binds and inhibits activin and myostatin; reduces myostatin-mediated muscle growth inhibition; promotes satellite cell activation and muscle fiber hypertrophy.
Research areas
Extreme muscle growth / hypertrophy; myostatin inhibition; muscular dystrophy (research); body composition; anti-aging (muscle preservation).
Regulatory / research status
Research / preclinical only
Half-life
~35 hours. Daily SC injection during cycle.
Storage
Lyophilized vial: store at -20°C long-term or 2-8°C short-term, protected from light.
Reported side effects
Significant risk: unregulated muscle growth, organ growth, cardiovascular strain; limited human safety data; potential cancer promotion via activin inhibition.
Documented central serous chorioretinopathy (vision impairment) case at a 10x dose; possible FSH suppression and theoretical fibrosis risk with chronic TGF-β inhibition; ~38 kDa glycoprotein with minimal injectable-peptide human data (most evidence is gene therapy). WADA-banned. Safety ratings summarize published clinical data, adverse-event reporting, and regulatory status. How PeptidePrices rates evidence. Research information only, not medical advice.
Study highlights
- Follistatin directly binds and neutralizes myostatin with a high-affinity Kd of ~5.84 × 10⁻¹⁰ M; the full follistatin protein is required for binding, and follistatin dose-dependently rescued muscle cell differentiation blocked by myostatin by restoring expression of Pax-3 and MyoD in chick developmental models.
- A Phase 1/2a clinical trial delivered follistatin via AAV1 intramuscular injection to six Becker muscular dystrophy patients; results showed improved 6-minute walk test scores (up to +125 m in some patients), reduced fibrosis, decreased central nucleation, and enlarged muscle fiber cross-sectional area at higher doses, with no serious adverse events.
- Transgenic pigs overexpressing human follistatin-344 in skeletal muscle showed increased lean meat content (~72.95% vs. 69.18% in controls) with no cardiac hypertrophy or reproductive abnormalities, demonstrating that muscle-specific follistatin expression selectively promotes skeletal myofiber hypertrophy without systemic pathology.
- Beyond myostatin, follistatin differentially antagonizes activin and GDF-11 through distinct structural domains (FSD1 for myostatin, FSD2 primarily for activin), broad follistatin expression also blocks activin signaling that regulates metabolism and reproduction, complicating its clinical application in humans.
Selected references
- Follistatin complexes Myostatin and antagonises Myostatin-mediated inhibition of myogenesis · Dev Biol, 2004
- A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy · Mol Ther, 2015
- The transgenic expression of human follistatin-344 increases skeletal muscle mass in pigs · Transgenic Res, 2017
- Differential antagonism of activin, myostatin and GDF-11 by wild-type and mutant follistatin · Endocrinology, 2008
- Mechanisms involved in follistatin-induced hypertrophy and increased insulin action in skeletal muscle · J Cachexia Sarcopenia Muscle, 2019
- Follistatin N terminus differentially regulates muscle size and fat in vivo · Exp Mol Med, 2017
Related pages